Volume 55, Issue 3, Pages (March 2009)

Slides:



Advertisements
Similar presentations
Volume 70, Issue 2, Pages (August 2016)
Advertisements

Early Detection of Prostate Cancer in 2007
Volume 58, Issue 3, Pages (September 2010)
Volume 165, Issue 5, Pages (May 2001)
Judith Bosschieter, André N. Vis, Henk G. van der Poel, Luc M
Volume 57, Issue 1, Pages (January 2010)
Volume 71, Issue 6, Pages (June 2017)
Volume 50, Issue 1, Pages (July 2006)
Volume 64, Issue 3, Pages (September 2013)
Volume 70, Issue 6, Pages (December 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 2, Pages (August 2010)
Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi  European Urology 
Volume 57, Issue 1, Pages (January 2010)
Volume 64, Issue 1, Pages (July 2013)
Volume 59, Issue 3, Pages (March 2011)
Volume 61, Issue 1, Pages (January 2012)
Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.
Volume 73, Issue 2, Pages (February 2018)
Volume 61, Issue 5, Pages (May 2012)
Volume 68, Issue 3, Pages (September 2015)
Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine  Carolyn D. Hurst, Fiona M. Platt, Margaret.
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Ashish M. Kamat, Sima Porten  European Urology 
Volume 61, Issue 2, Pages (February 2012)
Volume 61, Issue 4, Pages (April 2012)
Volume 65, Issue 6, Pages (June 2014)
Volume 61, Issue 3, Pages (March 2012)
Volume 63, Issue 4, Pages (April 2013)
Volume 63, Issue 1, Pages (January 2013)
Volume 61, Issue 2, Pages (February 2012)
Bladder Cancer: A Major Public Health Issue
Volume 66, Issue 2, Pages (August 2014)
Volume 71, Issue 6, Pages (June 2017)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 61, Issue 5, Pages (May 2012)
Volume 61, Issue 4, Pages (April 2012)
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Volume 68, Issue 1, Pages (July 2015)
Volume 63, Issue 5, Pages (May 2013)
Volume 59, Issue 4, Pages (April 2011)
Volume 52, Issue 3, Pages (September 2007)
Volume 64, Issue 3, Pages (September 2013)
Volume 55, Issue 3, Pages (March 2009)
Volume 71, Issue 6, Pages (June 2017)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 2, Pages (August 2014)
Volume 67, Issue 6, Pages (June 2015)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Volume 70, Issue 2, Pages (August 2016)
Volume 65, Issue 2, Pages (February 2014)
Volume 61, Issue 6, Pages (June 2012)
Volume 70, Issue 6, Pages (December 2016)
Volume 53, Issue 1, Pages (January 2008)
Volume 64, Issue 1, Pages (July 2013)
Volume 62, Issue 3, Pages (September 2012)
Volume 64, Issue 4, Pages (October 2013)
Volume 53, Issue 6, Pages (June 2008)
Volume 54, Issue 6, Pages (December 2008)
Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi  European Urology 
Volume 53, Issue 5, Pages (May 2008)
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Volume 51, Issue 5, Pages (May 2007)
Volume 52, Issue 4, Pages (October 2007)
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Volume 52, Issue 1, Pages (July 2007)
Volume 54, Issue 1, Pages (July 2008)
Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.
How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?  Shahrokh Shariat, Paolo Gontero, James.
Presentation transcript:

Volume 55, Issue 3, Pages 659-668 (March 2009) Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non- Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB])  Madelon N.M. van der Aa, Ellen C. Zwarthoff, Ewout W. Steyerberg, Merel W. Boogaard, Yvette Nijsen, Kirstin A. van der Keur, Antonius J.A. van Exsel, Wim J. Kirkels, Chris Bangma, Theo H. van der Kwast  European Urology  Volume 55, Issue 3, Pages 659-668 (March 2009) DOI: 10.1016/j.eururo.2008.05.001 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Prolonged duration between urine collection and microsatellite analysis (MA) and intravesical therapy negatively affect quality of MA in 19% (197/1012) of the samples. (a) Effect of time until analysis of urine sample. After 2 wk of delay MA failed in 80%. (b) Effect of intravesical immune/chemotherapy (iv therapy). In the first 6 mo after intravesical therapy, MA of 15% of urine samples failed, compared with 8% in samples from patients without iv therapy. A total of 88 patients was treated with intravesical therapy after transurethral resection. European Urology 2009 55, 659-668DOI: (10.1016/j.eururo.2008.05.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Flowchart showing the possible endpoints after completion of a microsatellite analysis (MA) series and the accompanying numbers of events. Endpoints were final (end of study or progressive recurrence) or temporary (change of MA result or urothelial carcinoma [NMI-UC]). Temporary endpoints and series ending with a histologically proven non-muscle invasive recurrence restarted a new MA series (*). European Urology 2009 55, 659-668DOI: (10.1016/j.eururo.2008.05.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier curve shows the proportion of recurrences in 458 microsatellite analysis (MA) events detected by consecutive continuous positive or negative results of MA. Time (in months) reflects the length of time of continuous MA results without visible suspicious lesion in the bladder. After 24 mo, 83% of recurrences were detected; 22% were missed. European Urology 2009 55, 659-668DOI: (10.1016/j.eururo.2008.05.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 Kaplan-Meier curves relating fibroblast growth factor receptor 3 (FGFR3) gene mutation status and tumour multifocality at entry to microsatellite analysis-detected recurrences. European Urology 2009 55, 659-668DOI: (10.1016/j.eururo.2008.05.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 5 Kaplan-Meier curves relating gender and smoking habits demonstrate that smoking habits determine the proportion of microsatellite analysis-detectable recurrences. European Urology 2009 55, 659-668DOI: (10.1016/j.eururo.2008.05.001) Copyright © 2008 European Association of Urology Terms and Conditions